Medipixel is a healthtech startup that aims to contribute to the improvement of the quality of human life by innovating diagnostic, and therapeutic procedures in cardiovascular disease with the power of AI. Consisting of a group of AI experts in computer vision, deep learning, and reinforcement learning, Medipixel is working on coronary intervention automation together with the best healthcare professionals at Asan Medical Center. Medipixel was founded in 2017, and is located at Seoul Startup Hub in Seoul, South Korea.
Global Healthtech Company improving the quality of human life by applying AI technology to healthcare
More than 80% of Team members are on R&D as either a research scientist or an engineer. On average, they have more than three years of experience in AI R&D, and most of them have working experience in companies like Samsung, LG, AhnLab, Lotte, etc. They have expertise in Deep Learning, Computer Vision, Reinforcement Learning, and Robotics.
Andy Song, Founder & CEO of Medipixel, studied at Korea University, and received his M.S. degree at Carnegie Mellon University majoring in Computer Science. Previsously he worked at LG Electronics, AhnLab, and was the CEO of Noritown Studio where he raised $2M from a Sillicon Valley VC, and partnered with global companies including Facebook, Disney, etc.
Seed Investment from OAC
Top 100 Finalists on K-Startup Challenge
Membership for Microsoft for Startups Program
Launched AI Bio Robot Project
Seed Investment from AI Angel Club
Matching Fund from Korea Venture Investment
Winner of Johnson & Johnson Seoul Innovation QuickFire Challenge
Seed Investment from HGI
Launched TIPS Project
Poster Session at TCT 2019 in San Francisco
Series A Funding from QUAD Investment Management
Medipixel has been the winner of Seoul Innovation QuickFire Challenge held by Johnson and Johnson in Nov, 2018.
“Seoul-based Medipixel is a start-up that applies artificial intelligence (AI) into robotic surgery, starting with percutaneous coronary intervention (PCI). Their AI-based robotic PCI solution helps surgeons choose the most suitable devices and guides devices precisely without human intervention.”
Johnson & Johnson Innovation Press Release
November 14, 2018